Karen Andersen was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick.
Morningstar Healthcare Strategist Karen Andersen discussed Amgen, Inc. AMGN on the show.
Andersen said that Amgen's pipeline of products was starting to turn around with recent FDA approvals and another major approval coming in the the summer of 2015 for a cholesterol treatment.
Andersen felt the market for the cholesterol lowering treatment would be worth at least $10 billion, with Amgen controlling approximately $4 billion of the market.
Amgen recently traded at $162.61, down 2.55 percent.
Listen to the show here:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
